tradmap

BGLC Earnings BioNexus Gene Lab Corp

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$0 -$0 $0 2023 2024
EPS
Revenue (annual)
$0 $7M $13M 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$3M -$945255 $1M $0 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$1 $0 $0 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Revenue (quarterly)
$0 $1M $3M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$3M -$1M $308463 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–10 of 10
Q2 20262026-06-30-0.342026-08-1410-Q
Q1 20262026-03-31-0.232026-05-1510-Q
Q3 20252025-09-30-1.082025-11-1410-Q
Q2 20262025-06-30-0.692026-08-1410-Q
Q1 20262025-03-31-0.352026-05-1510-Q
FY 20242024-12-31-0.092025-04-1510-K
Q3 20252024-09-30-0.702025-11-1410-Q
Q2 20252024-06-300.052025-08-1810-Q
Q1 20252024-03-31-0.012025-05-1510-Q
FY 20242023-12-31-0.172025-04-1510-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.